➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
Johnson and Johnson
Harvard Business School
Moodys

Last Updated: November 27, 2020

DrugPatentWatch Database Preview

Litigation for TREXIMET

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

US Court Litigation for TREXIMET

Patent Trial and Appeal Board Cases for TREXIMET

Patent Petitioner Status Filing Date Accorded Filing Date Patent Owner Trial Type Trial Number Decision Date Inventor Document Download
7,332,183 Graybar Pharmaceuticals, LLC   Start Trial 2015-11-12 11-12-2015 POZEN Inc. Inter partes review   Start Trial 05-06-2016 John Plachetka   Start Trial
>Patent >Petitioner >Status >Filing Date >Accorded Filing Date >Patent Owner >Trial Type >Trial Number >Decision Date >Inventor >Document Download

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
McKinsey
Boehringer Ingelheim
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.